ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

ripretinib

Also written as “Ripretinib” and “DCC-2618”.

Its studies are mostly in Gastrointestinal Stromal Tumors, led by 2 companies.

Drug pageRipretinib: every studyAll 9 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 3, since Nov 20, 20179 company-led studies, 3 open or runningNext primary completion: Dec 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Ono Pharmaceuticalits history only73 open or runningphase 3since Nov 20, 2017Oct 5, 2015Dec 2027phase 3 · NCT05734105
Zai Lab20 open or runningphase 2since Feb 21, 2020Feb 21, 2020none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Zai Lab only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.

  1. Jun 9, 2018Named ripretinibINNProposed as its International Nonproprietary Name in WHO's List 119 · before, DCC-2618
  2. Feb 21, 2020First study: phase 2 study in Gastrointestinal Stromal TumorsFirst studyNCT04282980 · 39 enrolled · China
  3. Nov 11, 2020Phase 2 study in Gastrointestinal Stromal TumorsNCT04633122 · 108 enrolled · China

TargetBeta

KIT →PDGFRA →read by rule
“An orally bioavailable switch pocket control inhibitor of wild-type and mutated forms of the tumor-associated antigens (TAA) mast/stem cell factor receptor (SCFR) KIT and platelet-derived growth factor receptor alpha (PDGFR-alpha; PDGFRa), ”NCIt, by rule
“Stem cell growth factor receptor inhibitor; Platelet-derived growth factor receptor alpha inhibitor”ChEMBL 37, by rule

Other programs on the same two targets

ProgramCompanyFurthest phaseStudies
regorafenibruleBayerphase 440
AvapritinibruleSanofiphase 410
masitinibruleAB Sciencephase 338
quizartinibruleDaiichi Sankyophase 322
seralutinibrulegb002-inc-a-wholly-owned-subsidiary-of-gossamer-bio-incphase 38

Studies

All 2 Zai Lab leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT04633122Gastrointestinal Stromal Tumors · China2CompletedJul 20, 2022108
NCT04282980Gastrointestinal Stromal Tumors · China2CompletedFeb 26, 202139

How it is read

Names in the registry

  • “Ripretinib”, 5 entries
  • “DCC-2618”, 5 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.